Agonist binding fraction of dopamine D2/3 receptors in rat brain: A quantitative autoradiographic study

Neurochemistry International

Volumn 56, Issue 6-7, 2010, Pages 747-752

  Minuzzi, Luciano ^a   Cumming, Paul ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

3H NPA; 3H raclopride; Autoradiography; Dopamine; LSD; Receptors

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; LYSERGIDE; PROPYLNORAPOMORPHINE; RACLOPRIDE; TRITIUM;

ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING COMPETITION; BINDING SITE; BRAIN REGION; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; FROZEN SECTION; LIGAND BINDING; MALE; NONHUMAN; OLFACTORY BULB; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; RECEPTOR BINDING; RECEPTOR OCCUPANCY;

ANIMALS; APOMORPHINE; AUTORADIOGRAPHY; BASAL GANGLIA; BINDING, COMPETITIVE; BRAIN; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; GUANYLYL IMIDODIPHOSPHATE; LYSERGIC ACID DIETHYLAMIDE; MALE; OLFACTORY PATHWAYS; RACLOPRIDE; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; TRITIUM;

RATTUS;

EID: 77952292007     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2010.01.010     Document Type: Article

References (64)

1. 2-dopamine receptor. Eur. J. Pharmacol. 1982, 81(3):493-498.
2. Booth R.G., Baldessarini R.J., Kula N.S., Gao Y., Zong R., Neumeyer J.L. Presynaptic inhibition of dopamine synthesis in rat striatal tissue by enantiomeric mono- and dihydroxyaporphines. Mol. Pharmacol. 1990, 92-101.
3. Burris K.D., Breeding M., Sanders-Bush E. (+)Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5HT1C receptor agonist. J. Pharmacol. Exp. Ther. 1991, 258(3):891-896.
4. 3H]N-n-propylnorapomorphine. Brain Res. 1986, 375(1):135-149.
5. Carta A.R., Pinna A., Tronci E., Morelli M. Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats. Neurology 2003, 61(11 Suppl. 6):S39-S43.
6. Casey P.J., Gilman A.G. G protein involvement in receptor-effector coupling. J. Biol. Chem. 1988, 263(6):2577-2580.
7. 3 receptor binding in the rat brain. Exp. Neurol. 1997, 146(1):74-80.
8. 3H-haloperidol. Life Sci. 1975, 17(6):933-1001.
9. 3H-N-n-propylnorapomorphine: a novel agonist ligand for central dopamine receptors. Eur. J. Pharmacol. 1979, 56(4):411-412.
10. 3H]LSD with serotonin receptors in human brain. Eur. J. Pharmacol. 1982, 82(1-2):77-80.
11. Cumming P., Wong D.F., Dannals R.F., Gillings N., Hilton J., Scheffel U., Gjedde A. The competition between endogenous dopamine and radioligands for specific binding to dopamine receptors. Ann. N. Y. Acad. Sci. 2002, 965:440-450.
12. Cumming P., Wong D.F., Gillings N., Hilton J., Scheffel U., Gjedde A. Specific binding of [(11)C]raclopride and N-[(3)H]propyl-norapomorphine to dopamine receptors in living mouse striatum: occupancy by endogenous dopamine and guanosine triphosphate-free G protein. J. Cereb. Blood Flow Metab. 2002, 22(5):596-604.
13. 11C]MNPA. Synapse 2009, 63(5):378-389.
14. 11C]MNPA in cynomolgus monkey. Nucl. Med. Biol. 2005, 32(4):353-360.
15. 3H]quinpirole binding sites in the rat brain. Synapse 1993, 14(2):113-120.
16. George S.R., Watanabe M., Di Paolo T., Falardeau P., Labrie F., Seeman P. The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinology 1985, 117(2):690-697.
17. 2 dopaminergic receptors and it potentiates dopamine-mediated prolactin secretion in lactotrophs in vitro. Life Sci. 1998, 63(3):215-222.
18. 11C]raclopride displacement studies: understanding the true mechanism. Mol. Imaging Biol. 2005, 7(1):45-52.
19. 2 receptors in vivo using positron emission tomography. J. Neurochem. 2006, 97(4):1089-1103.
20. Glennon R.A., Titeler M., McKenney J.D. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 1984, 35(25):2505-2511.
21. 2 dopamine receptors from the high- to the low-affinity state for dopamine agonists, using sodium ions and guanine nucleotide. J. Neurochem. 1985, 44(6):1925-1935.
22. 3H]raclopride binding to homogenates from human putamen and accumbens. Neurosci. Lett. 1992, 136(1):79-82.
23. 2 receptors in the rat brain. Eur. J. Pharmacol. 1985, 111(2):191-199.
24. 2 receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 1988, 12(5):559-568.
25. 2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 1994, 11(4):245-256.
26. 3H]-spiperone binding sites in the striatum and substantia nigra of the rat. Br. J. Pharmacol. 1983, 79(2):599-610.
27. 3H]N,n-propylnorapomorphine binding sites in rat striatum following phenoxybenzamine administration. Biochem. Pharmacol. 1983, 32(19):2973-2977.
28. Hamblin M.W., Leff S.E., Creese I. Interactions of agonists with D-2 dopamine receptors: evidence for a single receptor population existing in multiple agonist affinity-states in rat striatal membranes. Biochem. Pharmacol. 1984, 33(6):877-887.
29. 125I]LSD binding to serotonin and dopamine receptors in bovine caudate membranes. Neurochem. Int. 1985, 7(4):699-707.
30. Hoyer D., Boddeke H.W. Partial agonists, full agonists, antagonists: dilemmas of definition. Trends Pharmacol. Sci. 1993, 14(7):270-275.
31. 2 receptor selective antagonists: electrophysiological and behavioral studies. Synapse 1994, 17(1):43-61.
32. Hwang D.R., Narendran R., Huang Y., Slifstein M., Talbot P.S., Sudo Y., Van Berckel B.N., Kegeles L.S., Martinez D., Laruelle M. Quantitative analysis of (-)-N-(11)C-propyl-norapomorphine in vivo binding in nonhuman primates. J. Nucl. Med. 2004, 45(2):338-346.
33. Janson A.M., Fuxe K., Agnati L.F., Kitayama I., Harfstrand A., Andersson K., Goldstein M. Chronic nicotine treatment counteracts the disappearance of tyrosine-hydroxylase-immunoreactive nerve cell bodies, dendrites and terminals in the mesostriatal dopamine system of the male rat after partial hemitransection. Brain Res. 1988, 455(2):332-345.
34. 2 receptor upregulation induced by a partial meso-diencephalic hemitransection in the rat. Brain Res. 1994, 655(1-2):25-32.
35. 2 binding and dopamine turnover. Pharmacol. Biochem. Behav. 1996, 53(1):41-49.
36. 3H]N-propylnorapomorphine in the mouse brain. Evidence for labelling of central dopamine receptors. Eur. J. Pharmacol. 1981, 72(4):397-402.
37. 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem. Pharmacol. 1985, 34(13):2251-2259.
38. Kortekaas R., Maguire R.P., Cremers T.I., Dijkstra D., van Waarde A., Leenders K.L. In vivo binding behavior of dopamine receptor agonist (+)-PD 128907 and implications for the " ceiling effect" in endogenous competition studies with [(11)C]raclopride-a positron emission tomography study in Macaca mulatta. J. Cereb. Blood Flow Metab. 2004, 24(5):531-535.
39. Lahti R.A., Mutin A., Cochrane E.V., Tepper P.G., Dijkstra D., Wikstrom H., Tamminga C.A. Affinities and intrinsic activities of dopamine receptor agonists for the hD21 and hD4.4 receptors. Eur. J. Pharmacol. 1996, 301(1-3):R11-13.
40. 2-family receptor distribution in human postmortem tissue: an autoradiographic study. Neuroreport 1995, 6(18):2505-2512.
41. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metab. 2000, 20(3):423-451.
42. 2-like dopamine receptors in rat brain. J. Pharmacol. Exp. Ther. 1992, 262(3):929-935.
43. 3 dopamine receptors in rat brain and pituitary gland: a quantitative autoradiographic study. J. Pharmacol. Exp. Ther. 1993, 264(2):991-1001.
44. Liberatore G.T., Wong J.Y., Krenus D., Jeffreys B.J., Porritt M.J., Howells D.W. Tissue fixation prevents contamination of tritium-sensitive storage phosphor imaging plates. Biotechniques 1999, 26(3):432-434.
45. MacRae P.G., Spirduso W.W., Wilcox R.E. Reaction time and nigrostriatal dopamine function: the effects of age and practice. Brain Res. 1988, 451(1-2):139-146.
46. 2 receptor-mediated effects in the rat and implications for psychosis. Psychopharmacology (Berl.) 2005, 180(3):427-435.
47. Martin G.E., Bendesky R.J. Mouse locomotor activity: an in vivo test for dopamine autoreceptor activation. J. Pharmacol. Exp. Ther. 1984, 706-711.
48. 2 receptor in vitro. Synapse 2009, 63(11):998-1009.
49. 2 agonists and antagonists ex vivo. Nucl. Med. Biol. 2008, 35(1):11-17.
50. Mezzomo K., Cumming P., Minuzzi L. Comparison of the binding distribution of agonist and antagonist ligands for histamine H3 receptors in pig brain by quantitative autoradiography. Eur. J. Pharmacol. 2007, 564(1-3):75-79.
51. 3 binding sites in pig brain. Synapse 2005, 56(4):198-204.
52. 3 receptor PET radiotracer in non-human primate brain. Bioorg. Med. Chem. 2004, 12(1):95-102.
53. 11C]raclopride in baboons. J. Pharmacol. Exp. Ther. 2005.
54. 11C]-raclopride. Synapse 2004, 52(3):188-208.
55. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1998, Academic Press, San Diego.
56. 2 receptors in the rat central nervous system. Neuroscience 1989, 30(3):767-777.
57. 2 receptors in rat brain. Neurosci. Res. 1998, 30(3):201-211.
58. Seeman P. Brain dopamine receptors. Pharmacol. Rev. 1980, 32(3):229-313.
59. Seeman P., Ko F., Tallerico T. Dopamine receptor contribution to the action of PCP LSD and ketamine psychotomimetics. Mol. Psychiatry 2005, 10(9):877-883.
60. Seeman P., Tedesco J.L., Lee T., Chau-Wong M., Muller P., Bowles J., Whitaker P.M., McManus C., Tittler M., Weinreich P., Friend W.C., Brown G.M. Dopamine receptors in the central nervous system. Fed. Proc. 1978, 37(2):131-136.
61. Sibley D.R., De Lean A., Creese I. Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor. J. Biol. Chem. 1982, 257(11):6351-6361.
62. 3H-apomorphine labels both dopamine postsynaptic receptors and autoreceptors. Nature 1980, 288(5788):283-286.
63. Taylor K.M. Displacement of bound 14C-fluphenazine by biogenic amines and antipsychotic drugs in homogenates of brain tissue. Nature 1974, 252(5480):238-241.
64. Titeler M., Lyon R.A., Glennon R.A. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology (Berl.) 1988, 94(2):213-216.